Security
USRM · U.S. Stem Cell, Inc.
USRMOTCCommon stockCurrentCIK 1388319Updated Sep 26, 2026
Name history
BIOHEART, INC. · through Nov 2, 2015
USRM price & chart
Loading TradingView…
OTC:USRM on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 68,039Source | 50,999Source | 88,152Source | 89,843Source |
| Property, Plant and Equipment, NetUSD | — | 0Source | 0Source | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,133Source | 39,393Source | 18,570Source | 0Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,332Source | 1,213Source | 54,164Source | 48,208Source |
| Inventory, NetUSD | 980Source | 393Source | 5,418Source | 8,096Source |
| Assets, CurrentUSD | 68,039Source | 50,999Source | 88,152Source | 66,304Source |
| Prepaid Expense and Other Assets, CurrentUSD | 57,594Source | 10,000Source | 10,000Source | 10,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 14,813,435Source | 12,817,335Source | 11,667,444Source | 9,569,239Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 634,403Source | 503,525Source | 435,561Source | 417,725Source |
| Additional Paid in CapitalUSD | 127,137,483Source | 126,532,063Source | 124,499,655Source | 123,726,894Source |
| Retained Earnings (Accumulated Deficit)USD | -142,517,282Source | -139,801,924Source | -136,514,508Source | -133,624,015Source |
| Stockholders' Equity Attributable to ParentUSD | -14,745,396Source | -12,766,336Source | -11,579,292Source | -9,479,396Source |
| Liabilities and EquityUSD | 68,039Source | 50,999Source | 88,152Source | 89,843Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 14,077,891Source | 12,038,775Source | 10,847,524Source | 8,750,725Source |
| Accounts Payable, CurrentUSD | 1,624,583Source | 1,373,413Source | 1,282,010Source | 1,187,989Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,582,559Source | 1,951,390Source | 1,511,281Source | 1,115,526Source |
| Deferred Revenue, CurrentUSD | 3,000Source | 3,000Source | 3,000Source | 23,800Source |
| Deferred Revenue, NoncurrentUSD | 53,500Source | 56,500Source | 59,500Source | 62,500Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 0Source | 242,615Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 384,380Source | 556,556Source | 701,939Source | 824,426Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 587Source | -5,025Source | -2,678Source | -85,119Source |
| Increase (Decrease) in Accounts PayableUSD | 274,268Source | 73,195Source | 149,521Source | 344,536Source |
| Deferred Income Tax Expense (Benefit)USD | 1,524,561Source | 1,018,184Source | 1,162,141Source | -83,473Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -304,852Source | -1,057,939Source | -478,886Source | -1,210,994Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 0Source | 166,834Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 270,592Source | 1,078,762Source | 497,456Source | -312,986Source |
| Repayments of Long-term DebtUSD | — | 6,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,133Source | 39,393Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,113Source | 22,762Source | 40,989Source | 782,646Source |
| Additional Financial Items | ||||
| DepreciationUSD | — | 0Source | 0Source | 242,615Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | 21,474Source | 128,845Source |
| Gain (Loss) Related to Litigation SettlementUSD | -750,000Source | -422,722Source | 0Source | -698,937Source |
| Gain (Loss) on Extinguishment of DebtUSD | -447,494Source | -151,410Source | 182Source | 214,883Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 0Source | -23,539Source | 117,318Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -2,857,943Source | -3,287,416Source | -2,890,493Source | -3,835,337Source |
| Nonoperating Income (Expense)USD | -1,137,459Source | -1,151,558Source | -490,252Source | -418,481Source |
| Operating ExpensesUSD | 1,778,766Source | 2,284,577Source | 2,613,211Source | 5,153,912Source |
| Proceeds from Contributed CapitalUSD | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | 85,000Source | 275,000Source | 0Source | 50,000Source |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Total RevenueUSD | 82,049Source | 200,749Source | 277,087Source | 3,072,293Source |
| Cost of RevenueUSD | 23,767Source | 52,030Source | 64,117Source | 1,335,237Source |
| Selling, General and Administrative ExpenseUSD | 1,778,766Source | 2,284,577Source | 2,613,211Source | 4,454,712Source |
| Operating Income (Loss)USD | -1,720,484Source | -2,135,858Source | -2,400,241Source | -3,416,856Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -2,857,943Source | -3,287,416Source | -2,890,493Source | -3,835,337Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -2,857,943Source | -3,287,416Source | -2,890,493Source | -3,835,337Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 0Source |
| Gain (Loss) Related to Litigation SettlementUSD | -750,000Source | -422,722Source | 0Source | -698,937Source |
| Gross ProfitUSD | 58,282Source | 148,719Source | 212,970Source | 1,737,056Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 0Source | -23,539Source | 117,318Source |
| Interest ExpenseUSD | 689,977Source | 1,000,148Source | 488,369Source | 981,001Source |
| Nonoperating Income (Expense)USD | -1,137,459Source | -1,151,558Source | -490,252Source | -418,481Source |
| Operating ExpensesUSD | 1,778,766Source | 2,284,577Source | 2,613,211Source | 5,153,912Source |
| Research and Development ExpenseUSD | — | 0Source | 0Source | 263Source |